$KMTS

Webster Brian Daniel sold $1.3M of KMTS

Webster Brian Daniel (See Remarks) sold 51,900 shares of KESTRA MEDICAL TECHNOLOGIES, LTD. (KMTS) at an average of $24.52 ($24.47–$25.98, $1.27M total) across 3 trades on 2026-08-04.

Original reporting
SEC EDGAR · Webster Brian Daniel
Published Aug 6, 2026, 10:59 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 6, 2026, 11:14 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$KMTS
Neutral
medium confidence
Mentioned
$KMTS
Relevance
6/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$KMTSNeutralLow
01

Why it matters

Traders may briefly reassess sentiment around insider behavior, but there is no new operational or financial information to reprice the business.

02

Market read

A disclosed insider sale can move short-term sentiment, but without any accompanying fundamental catalyst, expected impact is modest.

03

What to watch

The article does not state whether the insider’s remaining holdings are subject to other arrangements, nor does it provide context on prior sale frequency or total compensation-driven selling.

Relevance 6/10Novelty 3/10Timing: Filed on 2026-08-06 for sales executed 2026-08-04.

Background

The article is a SEC Form 4 insider transaction disclosure for Kestra Medical Technologies, reporting an open-market sale by an officer/director.

Company-level read

Ticker impact

$KMTSNeutralMedium confidence
Context

Webster Brian Daniel, an officer/director of Kestra Medical Technologies, sold about 51,900 shares in open-market trades totaling $1.27M.

Expected impact

Likely limited near-term impact; any effect would be sentiment-driven and typically fades unless paired with other disclosures.

Evidence & confidence

The filing is a primary-source insider transaction, but the article provides no earnings, guidance, deal, or regulatory catalyst, and insider sales are often non-informational.

Market effects

No sector-level signal; this is company-specific insider activity without accompanying operational news.

None indicated.

None indicated.

Counterpoint

The absence of a stated 10b5-1 plan does not necessarily imply negative information; insiders may sell for diversification, taxes, or planned liquidity needs.

Key entities

  • Kestra Medical Technologies, Ltd.

    KMTS, the company whose insider transaction is disclosed on Form 4.

  • Webster Brian Daniel

    Officer and director who sold 51,900 shares in open-market trades totaling $1,272,587.76.

Related articles

$KMTSMedAI 8/10

Kestra Medical Technologies Q4 Earnings Call Highlights

Kestra Medical Technologies (NASDAQ:KMTS) reported a Q4 GAAP net loss of $38.8 million and adjusted EBITDA loss of $26.7 million. CFO Vaseem Mahboob said gross margin should rise steadily and reiterated confidence in gross margins above 70% over the next few years. The company guided FY2027 revenue to $137 million, up 44% from FY2026, and added a $200 million term loan facility.

$KMTSMed

Kestra Medical Technologies Ltd (KMTS) Q4 2026 Earnings Call Highlights: Record Revenue

Kestra Medical Technologies (KMTS) reported Q4 2026 call highlights. CFO Vaseem Mahboob said fiscal 2027 guidance targets $137 million revenue, driven by prescription volume growth, in-network mix, revenue cycle management improvements, and field expansion, with 44% growth. CEO Brian Webster discussed WCD guideline support, share gains, adding ~40 reps, and refinancing to cut cost of capital by 24% while keeping an M&A option open.

$KMTSMed

Kestra Medical (KMTS) Q4 2026 Earnings Call Transcript

Kestra Medical (KMTS) discussed its FY26 results on an earnings call. Revenue was $95 million for the year, up 59% from FY25, and $28.6 million in Q4, up 66% year over year. Gross margin rose to 51.4% for FY26 (up about 11 pts). The company reported 6.3k prescriptions and expanding sales territories to about 130.

$KMTSMedAI 8/10

Kestra Medical Technologies Secures Up to $200 Million of Non-Dilutive Financing

Kestra Medical Technologies (Nasdaq: KMTS) announced a five-year, non-dilutive term loan facility managed by Pharmakon Advisors. It includes $75M funded at closing (used to retire a $45M loan plus fees), $25M available through July 2027, $50M through June 2028 subject to $150M trailing revenue, and a $50M acquisition tranche. Interest is SOFR plus 5.5% with a 3.25% floor; Kestra reported $262M cash/investments as of Apr. 30, 2026.